QOP
ABUS icon

Quinn Opportunity Partners’s Arbutus Biopharma ABUS Stock Holding History

Quinn Opportunity Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
255,214
-259,299
-50% -$1.14M 0.06% 211
2026
Q1 		$2.32M Hold
514,513
– – 0.12% 146
2025
Q4 		$2.47M Hold
514,513
– – 0.1% 161
2025
Q3 		$2.34M Buy
514,513
+50,000
+11% +$184K 0.17% 127
2025
Q2 		$1.44M Hold
464,513
– – 0.12% 160
2025
Q1 		$1.62M Buy
464,513
+59,634
+15% +$199K 0.11% 180
2024
Q4 		$1.32M Buy
404,879
+169,747
+72% +$624K 0.09% 176
2024
Q3 		$905K Buy
235,132
+70,000
+42% +$269K 0.09% 149
2024
Q2 		$510K Buy
+165,132
New +$495K 0.06% 174
2022
Q1 		– Sell
-276,485
Closed -$1.08M – 167
2021
Q4 		$1.08M Buy
+276,485
New +$1.07M 0.07% 139

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quinn Opportunity Partners's ABUS Position: Q2 2026 in Review

Quinn Opportunity Partners reduced its Arbutus Biopharma (ABUS) stake by 50% in Q2 2026, selling an estimated $1.14M and leaving 255,214 shares worth $1.23M. The position accounts for 0.06% of the portfolio, ranked #211.

Quinn Opportunity Partners first reported a position in ABUS in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.47M in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Quinn Opportunity Partners held 255,214 shares of Arbutus Biopharma worth $1.23M as of Q2 2026.
  • Quinn Opportunity Partners sold 259,299 Arbutus Biopharma shares in Q2 2026, an estimated $1.14M.
  • Arbutus Biopharma made up 0.06% of Quinn Opportunity Partners's portfolio in Q2 2026, its #211 holding.
  • Quinn Opportunity Partners first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 10 quarters since.
  • Quinn Opportunity Partners's Arbutus Biopharma position peaked at $2.47M in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.